Sobi and Apellis enter collaboration for global co-development and ex-US commercialisation of systemic pegcetacoplan in rare diseases with urgent need for new treatments
· Sobi obtains global co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan, a targeted C3 therapy · Apellis retains US commercialisation rights for systemic pegcetacoplan and worldwide commercialisation rights for ophthalmological pegcetacoplan (geographic atrophy program in phase 3) · The companies will jointly advance systemic pegcetacoplan in five parallel registrational programmes including two new haematological studies planned to start in 2021 (CAD and HSCT-TMA). These join ongoing registrational programmes in haematology (PNH), nephrology (IC-